Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B003 (PD-1/CTLA-4 bispecific antibody) in advanced solid tumors
NCT04606472Phase 1Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SI-B003 in solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 3 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
SI-B003
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04606472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606472.